Array to buy rights to encorafenib

Array BioPharma Inc. (Nasdaq: ARRY) will acquire the worldwide rights to encorafenib from Novartis. The stock price soared $1.87 to $6.92.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.